News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
A 52-week weekly chart puts the move in longer context, with momentum improving but confirmation still measured.
This article provides a company profile for Valion Bio Inc. (VBIO), detailing its operations as a bio-electronic health-tech company developing micro current therapy solutions. It includes key financial facts such as market capitalization, 52-week high and low prices, current and previous day's stock prices, …
Lionheart Holdings Class A Ordinary Shares (NASDAQ:CUB) experienced a significant surge in short interest in July, increasing by 610.8% to 18,268 shares, although this represents only about 0.1% of its total shares. Analyst sentiment for CUB remains negative, with a consensus "Sell" rating, despite …
JPMorgan Chase & Co. has raised its price target for Helios Technologies (NYSE:HLIO) to $110.00 from $100.00, maintaining an "overweight" rating and implying a significant upside. This comes after Helios Technologies reported strong quarterly earnings, beating analyst estimates with an EPS of $0.88 and …
Valion Bio Inc. (NASDAQ:VBIO) is commencing a safety study for its drug Entolimod, aimed at treating radiation-induced gastrointestinal injury. The study, funded by a government program, will confirm the drug's tolerability in animals, with a therapeutic study to follow and top-line data expected in …
Valion Bio announced that the U.S. government is funding studies through AFRRI/NIAID to evaluate Entolimod for radiation-induced gastrointestinal (GI) injury. These studies, including a safety study starting this week and a therapeutic study to follow, aim to determine Entolimod's effectiveness in supporting survival and …
Valion Bio (Nasdaq: VBIO) announced that the U.S. government-funded Armed Forces Radiobiology Research Institute (AFRRI) program, under a NIAID contract, will begin evaluating Entolimod for lethal radiation-induced gastrointestinal (GI) injury. A safety study is set to start this week, followed by a therapeutic study …
This article reports on Xilio Therapeutics Inc.'s Form 8K filing for August 12. It notes the company's stock symbol as XLO, which saw a -1.42% change. The content primarily serves as a placeholder or announcement regarding the SEC filing.
Xilio Therapeutics reported its Q2 2026 financial results, showing $18.7 million in collaboration revenue and a net loss of $6.4 million. The company held $136.0 million in cash and cash equivalents, expecting this to fund operations into Q1 2028. Key business highlights include FDA …
Xilio Therapeutics reported its Q2 2026 financial results and provided updates on its pipeline, including FDA clearance for XTX501, a bispecific PD-1 / masked IL-2, with dosing expected in H2 2026. The company also announced advancing IND-enabling studies for two masked T cell engager …
Key Points Interested in Lion Finance Group PLC? Here are five stocks we like better. Strong Q2 performance: Revenue rose 23.4% year over year, profit increased 20.6%, and loans and deposits grew 23% and 26.8%, respectively. The 0.6% quarterly cost of risk was below …
Vermilion Energy Inc. (TSX: VET) saw its stock decline by 1.25% on August 11, 2026, due to broad energy market volatility, weak investor sentiment, and geopolitical tensions, particularly surrounding the Middle East and the Strait of Hormuz. Despite the company's strong operational execution, diversified …
Wasatch Advisors LP significantly reduced its stake in Helios Technologies (HLIO) by 17.4% in the second quarter, selling 138,923 shares but still retaining a substantial holding valued at approximately $58.9 million. This comes as Helios Technologies exceeded its second-quarter earnings and revenue expectations, and …
Catrina Marie Ralston, Senior Vice President at CONSUMER PORTFOLIO SERVICES, INC. (NASDAQ:CPSS), sold a total of $13,138 worth of company stock across two transactions in August 2026. Following these sales, Ms. Ralston directly holds 71,879 shares. The company recently reported a significant increase in …
A Valion Bio, Inc. shareholder group, including 3i, LP, Tumim Stone Capital, 3i Management, and Maier J. Tarlow, has filed an amended Schedule 13D, disclosing beneficial ownership of 9.9% of the company's common stock. The amendment reveals a proposal by 3i, LP to invest …
This article provides a stock quote for Valion Bio, Inc. (Nasdaq: VBIO), showing its current trading information, including price, volume, and performance metrics. It also features recent news headlines related to the company, such as a press release about U.S. government-funded Entolimod studies, and …
This article provides an AI-generated analysis of Medallion Financial Corp. (NASDAQ: MFIN), indicating strong near and mid-term sentiment that could lead to long-term positive performance. It highlights compelling upside potential with no remaining resistance levels above the current price. The report also outlines specific …
TWLO Q2 Deep Dive: AI Adoption and Platform Expansion Drive Revenue Acceleration Customer engagement platform Twilio (NYSE:TWLO) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 22% year on year to $1.50 billion. On top of that, next quarter's revenue …
Sharemaestro market context Trend signal active 52 weeks +131.1%Earnings Call Insights: Helios Technologies (HLIO) Q2 2026 MANAGEMENT VIEW * "We delivered another strong set of results in the second quarter" and "based on the solid first half results and improving visibility into the balance of the year, we are raising our full …
Helios Technologies (HLIO) reported strong second-quarter 2026 results, surpassing analyst estimates for both earnings and revenue. The company saw a 49% year-over-year increase in adjusted earnings per share and a 9% rise in revenues, driven by broad-based sales growth across its Electronics and Hydraulics …
Key Points Interested in Lion Finance Group PLC? Here are five stocks we like better. Strong Q2 performance: Revenue rose 23.4% year over year, profit increased 20.6%, and loans and deposits grew 23% and 26.8%, respectively. The 0.6% quarterly cost of risk was below …
Search by ticker symbol or company name and select a result to open its chart.